These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2191848)

  • 1. Treatment approaches to reflux oesophagitis.
    Lieberman D
    Drugs; 1990 May; 39(5):674-80. PubMed ID: 2191848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of gastro-oesophageal reflux disease.
    Klinkenberg-Knol EC; Festen HP; Meuwissen SG
    Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic principles in gastroesophageal reflux].
    Chassany O; Elkharrat D; Bergmann JF; Segrestaa JM
    Rev Med Interne; 1995; 16(12):960-70. PubMed ID: 8570962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole for maintenance of remission of erosive oesophagitis.
    Freston JW; Jackson RL; Huang B; Ballard ED
    Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of gastro-oesophageal reflux disease.
    De Giorgi F; Savarese MF; Atteo E; Leone CA; Cuomo R
    Acta Otorhinolaryngol Ital; 2006 Oct; 26(5):276-80. PubMed ID: 17345932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audit of reflux oesophagitis at 4 years.
    Pace F; Bollani S; Manzionna G; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):355-60. PubMed ID: 9789126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of reflux esophagitis.
    Vantrappen G; Janssens J
    Digestion; 1985; 32 Suppl 1():51-8. PubMed ID: 2866136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of gastroesophageal reflux disease: options and priorities.
    Thomson AB
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():14-23. PubMed ID: 1349550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis.
    Frazzoni M; Bertani H; Manta R; Mirante VG; Frazzoni L; Conigliaro R; Melotti G
    Dig Liver Dis; 2014 Jul; 46(7):596-602. PubMed ID: 24709005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease.
    Savarino V; Dulbecco P
    Digestion; 2004; 69 Suppl 1():9-16. PubMed ID: 15001830
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.